Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas C Bauer

Showing results (21-30 of 339) with videos related to

Pageof 34
Sort By:
Mayo Clinic Proceedings|October 11, 2002
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Byron Cryer, Douglas C Bauer
Annals of Internal Medicine|October 2, 2002
Quality indicators for management of osteoporosisDouglas C Bauer, Eric Orwoll
The Journal of Clinical Endocrinology and Metabolism|May 2, 2013
Subclinical hypothyroidism and cardiovascular risk: how to end the controversyNicolas Rodondi, Douglas C Bauer
Current Osteoporosis Reports|February 2, 2021
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?Douglas C Bauer, Bo Abrahamsen
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 20, 2008
Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapyDouglas C Bauer, Eric Vittinghof
The American Journal of Medicine|October 7, 2004
Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular eventsNicolas Rodondi, Douglas C Bauer
JAMA Internal Medicine|May 27, 2025
Denosumab and Fracture Prevention in Primary Care PracticeDouglas C Bauer, Kristine E Ensrud
The New England Journal of Medicine|April 10, 2024
Testosterone Treatment and Fractures in Men with Hypogonadism. ReplyPeter J Snyder, Douglas C Bauer
Current Osteoporosis Reports|January 31, 2012
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapyJohn T Schousboe, Douglas C Bauer
The American Journal of Medicine|December 21, 2020
The ReplyBaris Gencer, Douglas C Bauer, Nicolas Rodondi
Pageof 34

Showing results (21-30 of 339) with videos related to

Sort By:
Pageof 34
Mayo Clinic Proceedings|October 11, 2002
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Byron Cryer, Douglas C Bauer
Annals of Internal Medicine|October 2, 2002
Quality indicators for management of osteoporosisDouglas C Bauer, Eric Orwoll
The Journal of Clinical Endocrinology and Metabolism|May 2, 2013
Subclinical hypothyroidism and cardiovascular risk: how to end the controversyNicolas Rodondi, Douglas C Bauer
Current Osteoporosis Reports|February 2, 2021
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?Douglas C Bauer, Bo Abrahamsen
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 20, 2008
Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapyDouglas C Bauer, Eric Vittinghof
The American Journal of Medicine|October 7, 2004
Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular eventsNicolas Rodondi, Douglas C Bauer
JAMA Internal Medicine|May 27, 2025
Denosumab and Fracture Prevention in Primary Care PracticeDouglas C Bauer, Kristine E Ensrud
The New England Journal of Medicine|April 10, 2024
Testosterone Treatment and Fractures in Men with Hypogonadism. ReplyPeter J Snyder, Douglas C Bauer
Current Osteoporosis Reports|January 31, 2012
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapyJohn T Schousboe, Douglas C Bauer
The American Journal of Medicine|December 21, 2020
The ReplyBaris Gencer, Douglas C Bauer, Nicolas Rodondi
Pageof 34